The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / DEA Proposes Cutting Production of Come Opioids

DEA Proposes Cutting Production of Come Opioids

August 7, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year.

You Might Also Like
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
  • U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids
  • U.S. Justice Department to Push Prosecutors on Opioids

The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to combat the epidemic of abuse, overdose and addiction.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Under the Controlled Substances Act, which organizes drugs into groups based on risk of abuse or harm, most opioids come under the Schedule II category. The higher the category, the bigger the risk.

Demand for certain Schedule II opioid painkillers including morphine, fentanyl, oxycodone and hydrocodone has dropped after the imposition of measures such as prescription drug monitoring programs, the DEA said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Still, opioid overdose kills 142 Americans a day, and drug overdoses now surpass deaths caused by gun homicides and car crashes combined, according to a White House commission formed to combat drug addiction and the opioid crisis.

The DEA’s proposed production quotas for Schedule I and II substances reflect the amount needed to meet the United States’ medical, scientific, industrial, export and reserve requirements, the agency said.

Members of the public can comment on the proposal over the next 30 days.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The DEA recommendation comes about two months after the U.S. Food and Drug Administration took the rare step of asking a drugmaker to withdraw its opioid painkiller from the market, citing the public health crisis. Endo International Plc in early July agreed to pull the drug, Opana ER (oxymorphone hydrochloride).

Filed Under: Analgesics, Drug Updates, Safety Tagged With: Opioid abuse, opioid crisis, Opioids

You Might Also Like:
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
  • U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids
  • U.S. Justice Department to Push Prosecutors on Opioids
  • U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.